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Abstract
Background:  Skeletal muscle depletion is an important complication of chronic obstructive
pulmonary disease (COPD) but little prospective data exists about the rate at which it occurs and
the factors that promote its development. We therefore prospectively investigated the impact of
disease severity, exacerbation frequency and treatment with corticosteroids on change in body
composition and maximum isometric quadriceps strength (QMVC) over one year.
Methods: 64 patients with stable COPD (FEV1 mean (SD) 35.8(18.4) %predicted) were recruited
from clinic and studied on two occasions one year apart. Fat free mass was determined using
bioelectrical impedance analysis and a disease specific regression equation.
Results: QMVC fell from 34.8(1.5) kg to 33.3(1.5) kg (p = 0.04). The decline in quadriceps strength
was greatest in those with the highest strength at baseline (R -0.28 p = 0.02) and was not correlated
with lung function, exacerbation frequency or steroid treatment. Decline in fat free mass was
similarly higher in those with largest FFM at baseline (R = -0.31 p = 0.01) but was more strongly
correlated with greater gas trapping (R = -0.4 p = 0.001). Patients with frequent exacerbations (>1
per year) (n = 36) experienced a greater decline in fat free mass compared to infrequent
exacerbators (n = 28) -1.3(3.7)kg vs. +1.2(3.1)kg (p = 0.005), as did patients on maintenance oral
steroids (n = 8) -2.8(3.3) kg vs. +0.2(3.5) kg (p = 0.024) whereas in those who stopped smoking (n
= 7) fat free mass increased; +2.7(3.1) kg vs. -0.51(3.5) kg (p = 0.026).
Conclusion: Decline in fat free mass in COPD is associated with worse lung function, continued
cigarette consumption and frequent exacerbations. Factors predicting progression of quadriceps
weakness could not be identified from the present cohort.
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Background
It is well established that chronic obstructive pulmonary
disease (COPD) has systemic consequences, one of which
is fat free mass depletion [1], which is independently asso-
ciated with excess mortality [2] and impaired quality of
life [3]. A number of studies have identified weight loss
and low BMI as independent predictors of mortality [4,5]
and patients who failed to gain weight after a program of
nutritional support also had a worse prognosis [6]. Skele-
tal muscle is a major component of fat free mass and skel-
etal muscle depletion is itself associated with reduced
exercise capacity [7-9], while thigh muscle bulk has been
found to predict survival [10]. Very recently quadriceps
strength itself has been demonstrated to be a predictor of
mortality in COPD [11]. A variety of mechanisms have
been postulated, including disuse atrophy, poor nutri-
tion, oral corticosteroid treatment [12], systemic inflam-
matory mediators [1] and more recently, genetic factors
[13,14].
However no prospective data are available regarding the
rate of decline of strength in COPD and the factors that are
responsible for it. Short term studies have shown that
exacerbations of COPD are associated with increased
inflammatory mediators and acute and partially reversible
reductions in both quadriceps [15] and handgrip strength
[16]. Since exacerbations are also associated with immo-
bility, negative nitrogen balance [16] and reduced mobil-
ity, it seems reasonable to hypothesize that the
development of skeletal muscle depletion over time
would be associated with exacerbation frequency.
Based on this interpretation of the literature, this study
evaluated various a priori determined factors to determine
their utility in predicting decline in fat free mass and
quadriceps strength. The factors to be evaluated were indi-
ces of lung function, oral corticosteroid exposure and hav-
ing frequent exacerbations
Methods
Patients were recruited from clinics at The Royal Bromp-
ton Hospital if they had COPD, defined according to the
GOLD guidelines [17], without significant diagnosed co-
morbidity (including heart failure, neuromuscular disease
and other conditions likely to impact on skeletal muscle)
or evidence of exacerbation in the preceding month. The
Royal Brompton and Harefield Hospitals' Research Ethics
Committee approved the study, which was conducted in
accordance with the Helsinki declaration and all patients
gave their written informed consent. Clinical information
including treatment, health related quality of life (St
George' Respiratory Questionnaire [18]), number of exac-
erbations in the previous year (defined as discrete epi-
sodes of worsening of respiratory symptoms leading to
treatment with antibiotics), and average daily dose (ADD)
of oral prednisone received was obtained from patients
through a structured interview with reference to their hos-
pital records relating to any outpatient appointments in
the intervening period. Patients were studied at baseline
and tests repeated at a one year follow up visit. None of
the patients took part in a pulmonary rehabilitation
course during the follow up period. Baseline data from
some of the subjects in this study has been published pre-
viously [11,13,14,19].
Spirometry was obtained using a pneumotachograph with
flow integration, lung volumes by whole body plethys-
mography and gas transfer with a single breath technique
(CompactLab System, Jaeger, Germany). Blood gas ten-
sions were measured in arterialised earlobe capillary sam-
ples. Fat free mass (FFM) was determined using
bioelectrical impedance analysis (Bodystat 1500, Bodys-
tat, Isle Of Man, UK) and a disease specific regression
equation [20].
Maximum isometric quadriceps strength (QMVC) was
measured with subjects seated, trying to extend their dom-
inant leg as hard as possible against an inextensible strap
connecting their ankle to a strain gauge (Strainstall Ltd,
Cowes, UK) [21]. The signal was amplified and passed to
a computer running LabView 4 software (National Instru-
ments, Austin, Texas). The force generated was visible to
subject and investigator for positive feedback and
repeated efforts were made with vigorous encouragement
until there was no improvement in performance. Efforts
were sustained for at least 5 seconds. Subjects rested for
about 30 seconds between each contraction. According to
convention, values were normalised for body weight
(QMVC %predicted) [21].
To assess respiratory muscle strength, maximum sniff
nasal (SNiP) and static expiratory (PEmax) mouth pres-
sures were also determined [22,23].
Statistical analysis
The main outcome measures were change in FFM and
QMVC. Analysis was performed using StatView 5.0 (Aba-
cus concepts, Inc., Berkeley, CA, USA) and focused on the
effect of exacerbation rate, oral steroid exposure and dis-
ease severity (%predicted values of gas transfer (TLCO),
forced expiratory volume in one second (FEV1), and func-
tional residual capacity (FRC). Frequent exacerbators were
defined a priori as those having two or more exacerbations
per year consistent with international guidelines [24].
Change in FFM and QMVC were related both to baseline
patient characteristics and to change in these parameters
over time using forward stepwise regression analysis
including parameters with a p value of < 0.1 by univariate
analysis. A p value of < 0.05 was taken to be significant.Respiratory Research 2007, 8:25 http://respiratory-research.com/content/8/1/25
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Results
Follow up
Of 109 patients studied at baseline, five (4.6%) were
actively excluded from analysis because they developed
significant co morbidity during the year (malignancy or
cardiac disease) and nine (8.3%) patients died during the
follow up period. We did not seek to follow up two
patients who had moved to a distant part of the country
and were no longer patients of the hospital. Thirteen
(11.9%) declined to come back for further testing. Of
these, two felt too unwell to come, two declined to travel
and nine gave no specific reason. For 16 of the remaining
80 patients, clinical data, lung function and weight were
available but not measures of strength or fat free mass.
This was primarily for logistical reasons, for example dif-
ficulty coordinating visits to the lab with patients' clinic
appointments. The group that was not followed up did
not differ significantly from those who were, in terms of
baseline lung function, GOLD stage, strength, body com-
position, or ADD steroids and exacerbation rate in the
year prior to the start of the study (Table 1).
The results given henceforth in this paper are for the 64
patients in whom both baseline and follow up measure-
ments of FFM were performed. 22 (34 %) were female,
mean cigarette exposure was 47 (28) pack years and 16
(25%) were continued smokers. At baseline, 43 (67%)
were using inhaled steroids, seven (10%) were taking reg-
ular oral steroids (≤ 10 mg prednisone per day), 19 (30%)
had a nebuliser and 12 (19%) were on long term home
oxygen therapy. 1,13,15,35 patients were in GOLD stages
1 to 4 respectively. Other baseline characteristics are given
in Table 1.
Factors associated with strength and body composition at 
baseline
At baseline 23 (36%) of the patients studied had fat free
mass depletion (defined as a fat free mass index (FFMI) <
15 kg.m-2 for women or < 16 kg.m-2 for men). The FFM
deplete group also had significantly worse gas transfer;
%predicted TLCO 30.9 (16.8) vs. 44.5 (19.4) (p = 0.008),
but did not differ significantly in other lung function
parameters or in terms of oral steroid exposure or reported
exacerbation rate in the year prior to the start of the study.
Patients with FFM depletion had significantly weaker
quadriceps QMVC 27.5 (9.3) kg vs. 38.7 (11.3) kg (p =
0.0002) and expiratory muscle strength MEP 79.1(31.2)
cmH2O vs. 109.7 (46.4) cmH2O (p = 0.016) but SNiP did
not differ significantly 64.6 (20.0) cmH2O vs. 68.3 (19.5)
cmH2O (p = 0.5).
Quadriceps strength at baseline was significantly corre-
lated with FFM (r2 0.35 p < 0.0001) and %predicted TLCO
(r2 0.1 p = 0.04), but not with lung volume or airflow
obstruction, nor with having frequent exacerbations,
ADD prednisone in the preceding year and smoking his-
tory. Only FFM was retained as an independent variable in
stepwise regression analysis.
Change in quadriceps strength during follow up
Over the course of a year mean (SD) QMVC fell signifi-
cantly from 34.8 (1.5) kg 66.3 (17.9) % predicted, to 33.3
(1.5) kg 62.3 (17.7) %predicted (p = 0.04 and 0.009
respectively) (Table 1).
Decline in QMVC was only correlated with baseline
QMVC (r2 0.1 p = 0.025) with the greatest decline in the
patients who were strongest at baseline. 36 (56%) of the
patients were defined as frequent exacerbators. Decline in
QMVC in this cohort was not associated with disease
severity, having frequent exacerbations or corticosteroid
treatment.
Change in fat free mass during follow up
Decline in FFM was associated with a higher baseline fat
free mass, worse quality of life (judged as higher SGRQ
total score), worse lung function, being on maintenance
Table 1: Strength and body composition at baseline and one year follow up
Subjects not followed up n = 43 Baseline n = 64 One Year follow up n = 64
QMVC (kg) 32.2 (12.8) 34.8 (1.5) 33.3 (1.5)*
QMVC %predicted 64.6 (20.8) 66.3 (17.9) 62.3 (17.7)*
BMI (kgm-2) 23.5 (4.4) 24.3 (5.2) 24.7 (5.4)
Weight (kg) 67.1 (15.0) 70.5 (15.7) 71.4 (15.9)
FFM (kg) 46.7 (8.3) 47.5 (8.3) 47.3 (7.9)
SNiP (cmH2O) 61.5 (19.6) 67.4 (19.5) 69.9 (21.9)
PEmax (cmH2O) 89.2 (30.2) 98.9 (43.9) 100.0 (44.3)
Age (years) 65.5 (9.9) 62.0 (9.4)
FEV1 %predicted 40.5 (17.9) 36.0 (18.4) 36.3 (19.4)
TLCO %predicted 39.8 (19.9) 40.1 (19.3) 40.5 (20.0)
FRC %predicted 181 (32) 176 (41) 175 (39)
PaCO2 (kPa) 5.2 (1.1) 5.2 (0.9) 5.2 (0.9)
PaO2 (kPa) 9.4 (1.4) 9.4 (1.6) 9.2 (1.4)
QMVC – quadriceps maximum voluntary contraction, FFM – fat free mass, SNiP – sniff nasal pressure, PEmax – maximum expiratory pressure, FEV1 
– forced expiratory volume in one second, TLCO – carbon monoxide transfer factor, FRC functional residual capacity. Mean (SD). There was no 
significant difference at baseline between patients who were or were not followed up at one year. *p < 0.05 vs baseline.Respiratory Research 2007, 8:25 http://respiratory-research.com/content/8/1/25
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prednisone and having frequent exacerbations (Table 2)
(Figure 1).
The 8 patients on long term maintenance prednisone at
the one year follow up visit had a significantly greater
decline in FFM compared to the rest of the group; -
2.8(3.3) kg vs. +0.2(3.5) kg (p = 0.024). The ADD pred-
nisone received during follow up was median (range) 0
(0–26.1) mg.day-1. Changes in FFM did not differ signifi-
cantly between those who had (n = 32) or had not
received any prednisone during the year, being -0.86 (3.2)
kg vs. +0.54 (3.8) kg (p = 0.12) respectively. In addition,
to look for evidence of a dose response effect, ADD pred-
nisone was log transformed to normalize it (this also
excludes zero values). There was no correlation between
log transformed ADD prednisone and change in FFM.
Patients on maintenance oral prednisone were more
likely to be frequent exacerbators (Chi2 12.4 p < 0.001).
Seven patients stopped smoking during the follow up
period and experienced a significant increase in FFM com-
pared to the rest of the patients studied; +2.7 (3.1)kg vs. -
0.51(3.5)kg (p = 0.026). Comparing quitters to continued
smokers (n = 9) the change in FFM was +2.7(3.1)kg vs
+0.6(1.0)kg (p = 0.08).
By stepwise regression analysis, percent predicted FRC,
being on maintenance prednisone, smoking cessation
and baseline FFM were retained, with the equation ∆FFM
= -0.165 × (FFM) – 0.037 × (%predicted FRC) + 6.5 ×
(smoking cessation = 1) - 3.3 × (maintenance prednisone
= 1) explaining 46% of the variance (p < 0.0001).
Respiratory muscle strength
Measures of respiratory muscle strength are given in Table
1. There was no relationship between changes in SNiP or
PEmax and baseline respiratory muscle strength, pulmo-
nary function, or steroid exposure and exacerbation fre-
quency analyzed in the same manner as for quadriceps
strength.
Discussion
This study investigated changes in fat free mass and skele-
tal muscle strength in a cohort of patients with COPD
over one year's follow up. Skeletal muscle depletion was
common at baseline and was associated with a more
severe impairment in gas transfer. During follow up,
decline in fat free mass was independently associated with
more marked gas trapping, a higher FFM at baseline and
use of maintenance oral corticosteroids, whereas FFM
increased in patients who stopped smoking. An associa-
tion between frequent exacerbations and decline in FFM
was not retained as an independent correlate.
At baseline, quadriceps weakness was most marked in
those with reduced fat free mass and declined further over
the course of a year. The only parameter predicting decline
in QMVC during follow up was QMVC at baseline. Of
note the mean decline in QMVC was 4.3% which is signif-
icantly more than the 1–2% per annum anticipated in a
healthy aging population [25-27]. This greater decrease is
of considerable interest given that an association has been
demonstrated between quadriceps strength and mortality
in studies of healthy elderly subjects [28,29]. In the
former study a reduction in quadriceps force of 38 NM
(about twice that observed in our study) was associated
with a hazard ratio for death of 1.51 in men and 1.65 in
women. Recently an association between quadriceps
strength and mortality has also been found in patients
with COPD which was independent of lung function [11].
Methodological issues
Follow up data was not available for all of the patients
studied at baseline which could be a source of bias. Even
in shorter term studies of muscle strength in COPD follow
up has been problematic [15]. A number of arguments
can be made to offset the significance of this however.
Since the purpose of the study was to examine the natural
history of decline in patients with COPD, we excluded
those who developed significant co morbidity such as
cancer or cardiovascular disease which would themselves
have influenced strength or fat free mass. Moreover in a
significant proportion of those not followed up the rea-
sons were logistical, to do with coordinating laboratory
visits with clinic appointments and therefore 'random'
and unlikely to be a source of bias. It is acknowledged that
a proportion of patients declined to have further tests but
this group did not differ at baseline significantly from
those followed up so it is unlikely that this was a signifi-
cant source of confounding. In particular it should be
noted that a similar proportion of those followed up
(36%) and those not followed (37%) had fat free mass
depletion at baseline. We think it is unlikely therefore that
Table 2: Factors correlated with change in fat free mass
Rp
Baseline FFM -0.3 0.013*
SGRQ total score -0.27 0.04*
FEV1 (%predicted) 0.27 0.03*
TLCO (%predicted) 0.19 0.15
FRC (%predicted) -0.42 0.008*
ADD Prednisone -0.24 0.06
Frequent exacerbations -0.34 0.006*
All values given are those measured at baseline except the 
exacerbation rate which refers to exacerbations occurring during the 
period of follow up. FFM – fat free mass, SGRQ – St George's 
respiratory questionnaire, FEV1 – forced expiratory volume in one 
second, TLCO – carbon monoxide transfer factor, FRC – functional 
residual capacity. R values are for univariate analysis. Mean (SD). *p < 
0.05.Respiratory Research 2007, 8:25 http://respiratory-research.com/content/8/1/25
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Change in fat free mass over one year in frequent (≥ 2/yr)(A) and infrequent (B) exacerbators Figure 1
Change in fat free mass over one year in frequent (≥ 2/yr)(a) and infrequent (b) exacerbators. Horizontal bars 
represent mean values. * p = 0.005 comparing change in FFM in frequent and infrequent exacerbators.
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the findings of this study would have been skewed by an
uneven pattern of drop out.
We chose to define exacerbations as episodes of worsen-
ing of disease sufficient to cause patients to seek medical
assistance and receive a prescription for antibiotics. This
definition can therefore to some extent be criticized as
dependent on behaviour. On the other hand it has the
merit of incorporating an element of 'clinical signifi-
cance'. Other definitions and techniques such as diary
cards have been used and this remains an area of contro-
versy, but to date no consensus exists in the literature as to
which is the 'gold standard'. It seems unlikely that a differ-
ent definition would have caused any systematic differ-
ence in the results obtained. In addition it was possible in
most patients to correlate their reports of exacerbations
with the medical notes relating to clinic attendances in the
intervening year to increase accuracy. As part of their rou-
tine clinical care at clinic visits during the year patients
had been asked to recall exacerbations treated at home.
Thus at the end of the year a 'contemporary' record of
events was available to correlate with patients' recollec-
tion.
Bioelectrical impedance analysis has been shown to be
highly repeatable on consecutive days in patients with
COPD [30]. In healthy subjects, isometric quadriceps
force had a 95% repeatability coefficient of 7.6 kg in a
study of healthy controls with a mean strength of 93 kg
[31]. Limited data are available about the repeatability of
measures of quadriceps strength in this patient group.
QMVC measured on two occasions within 2 weeks of each
other in our lab in a group of 15 patients with COPD was
28.8(9.2) at baseline and 29.9(9.8) at 2 week follow up
with a Bland Altman coefficient of repeatability (1.96
times the SD of the difference between the measurements)
of 6.0 kg [32]. Given the gap between study visits it is
unlikely that there would have been a significant learning
effect to bias the results.
Activity levels might also be expected to impact on
changes in strength and body composition but these data
were not collected in this study.
Significance of findings
To our knowledge this is the first prospective study look-
ing at skeletal muscle impairment in patients with COPD
over a significant period of follow up. Other studies have
been short term [33,34], or where the effect of a therapeu-
tic intervention such as growth hormone or anabolic ster-
oids has been studied, the control group has also
undergone pulmonary rehabilitation [35-37].
Exacerbations of COPD are known to be associated with
negative nitrogen balance and elevated levels of cytokines
[15] and an association between systemic inflammation
and fat free mass depletion has previously been noted in
clinically stable COPD [38]. However frequent exacerba-
tions were not retained as an independent predictor of
FFM decline. This may be because mechanistically it is in
fact the prevailing 'stable state' that is more important
than these acute episodes. Patients with a higher FRC are
likely to have a greater work of breathing continually and
to be more limited by breathlessness. Alternatively, since
exacerbations tend to occur more frequently in more
severe disease it may be that our study was not large
enough to pick up a discrete exacerbation 'signal' among
other co-varying markers of disease severity such as FEV1,
SGRQ and in particular FRC.
Oral corticosteroids have been proposed as a significant
cause of skeletal muscle impairment in COPD [12]
although other studies have not found a correlation with
strength [13,39-41] and short courses in stable patients do
not appear to have any significant effect on muscle func-
tion [32]. Our study adds to the evidence that mainte-
nance oral steroid treatment may be harmful in COPD
with a significantly greater decline in FFM in this group.
Maintenance therapy has been shown to attenuate the
improvement in muscle bulk occurring with nutritional
supplementation during pulmonary rehabilitation [42]
and to increase the risk of death [43,44]. In the group as a
whole, who mostly received only short burst treatment
with corticosteroids, there was no association between
steroid exposure and fat free mass or strength, either at
baseline or during the follow up period, suggesting that
the latter strategy is less harmful. It remains possible that
maintenance corticosteroid treatment was a surrogate for
a history of frequent exacerbations.
The benefits of smoking cessation on decline in lung func-
tion are well established [45]. Our data suggests an addi-
tional benefit with a significant increase in FFM occurring
in the quitter group. Although weight gain following
smoking cessation is commonly described we are not
aware of any data showing an increase in FFM in COPD
patients who quit. The mechanism for this benefit apart
from increased appetite or exercise could be a reduction in
the systemic inflammation that is present even in appar-
ently healthy smokers [46].
Sniff nasal inspiratory pressure did not decline during the
course of this study. The diaphragm in COPD experiences
an increase in loading in contrast to the lower limb mus-
cles where disuse is an important feature. Our findings are
consistent with the view that systemic factors such as
inflammation are relatively unimportant in the aetiology
of muscle weakness or else that they have a synergistic
effect with disuse which spares the inspiratory muscles but
impacts on muscles of locomotion.Respiratory Research 2007, 8:25 http://respiratory-research.com/content/8/1/25
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It should be noted that by the time patients were enrolled
in this study they had already developed significant weak-
ness with mean QMVC only 66 percent predicted. In addi-
tion more than a third of them had significant nutritional
depletion. Given that baseline FFM was strongly corre-
lated with quadriceps strength at baseline, these two fac-
tors are clearly linked even if change over the period of
follow up appeared to be dependent on different factors.
A further question will be to investigate the interaction
between COPD and other co morbidities that occur fre-
quently in these patients and also impact on skeletal mus-
cle such as heart failure and vascular disease.
Conclusion
This study demonstrates a reduction in quadriceps
strength over one year of follow up greater than would be
anticipated in a healthy population. We do not know if
there is early rapid loss of strength which then slows or if
the decline is steady or if it is stepwise, perhaps in the con-
text of exacerbations. The pattern of decline may well dif-
fer in different disease phenotypes. Our model explained
only 46% of the decline in fat free mass over one year.
Because our patients were recruited from hospital rather
than primary care the population was inevitably weighted
towards patients with more severe disease and it is clear
that in order fully to understand the aetiology of muscle
weakness and fat free mass depletion, future studies will
need to enrol patients at an earlier point in the disease
process and for longer periods of follow up. This should
make it possible to understand better the role of factors
such as systemic inflammation or hormonal depletion.
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